Document:

Exhibit 10.1

 

 

 

FIRST AMENDMENT TO THE 

MARIJUANA COMPANY OF AMERICA, INC. EQUITY INCENTIVE
PLAN 

WHEREAS, Marijuana Company of America, Inc.
(“Company”) previously adopted the Marijuana Company of America, Inc. Equity Incentive Plan (“Plan”); and

WHEREAS, the Company desires to amend the Plan
to increase the number of Shares of Common Stock available for issuance thereunder by 2,500,000,000 shares;

WHEREAS, the stockholders of the Company have
approved the proposed amendment of the Plan to increase the number of Shares of Common Stock available for issuance thereunder by 2,500,000,000
shares; and

WHEREAS, the Company maintains the right to
amend the Plan pursuant to Section 12.2 therein;

NOW THEREFORE, Section 3 of the Plan is
deleted in its entirety and replaced with the following, effective September 12, 2022:

 

“4. Shares Subject to the Plan.

 

4.1 Maximum Share Limitations. Subject to appropriate
adjustments for stock splits or reverse stock splits, the maximum aggregate number of shares of Common Stock that may be issued and sold
under all Awards granted under the Plan shall be up to 3,000,000,000 Shares of Common Stock issued and sold under the Plan may be either
authorized but unissued shares or shares held in the Company’s treasury. To the extent that any Award involving the issuance of
shares of Common Stock is forfeited, cancelled, returned to the Company for failure to satisfy vesting requirements or other conditions
of the Award, or otherwise terminates without an issuance of shares of Common Stock being made thereunder, the shares of Common Stock
covered thereby will no longer be counted against the foregoing maximum share limitations and may again be made subject to Awards under
the Plan pursuant to such limitations.

 

4.2 Adjustments. If there shall occur any change
with respect to the outstanding shares of Common Stock by reason of any recapitalization, reclassification, stock dividend, extraordinary
dividend, stock split, reverse stock split or other distribution with respect to the shares of Common Stock, or any merger, reorganization,
consolidation, combination, spin-off or other similar corporate change, or any other change affecting the Common Stock, the Committee
may, in the manner and to the extent that it deems appropriate and equitable to the Participants and consistent with the terms of the
Plan, cause an adjustment to be made in (i) the maximum number and kind of shares provided in Section 4.1 hereof, (ii) the number and
kind of shares of Common Stock, or other rights subject to then outstanding Awards, (iii) the exercise or base price for each share or
other right subject to then outstanding Awards, and (iv) any other terms of an Award that are affected by the event. Notwithstanding the
foregoing, in the case of Incentive Stock Options, any such adjustments shall, to the extent practicable, be made in a manner consistent
with the requirements of Section 424(a) of the Code.”

IN WITNESS WHEREOF, this Amendment is hereby
executed by a duty authorized officer of the Company this 12th day of September 12, 2022.

 

	 	 	 
	MARIJUANA COMPANY OF AMERICA, INC.
	 	 
	By:	 	
    /s/ Jesus Quintero

	 
	Title: President and CEOExhibit 10.1

 

ACQUISITION
AGREEMENT

 

This
Acquisition Agreement (this “Agreement”), is entered into as of September 8, 2022 (the “Execution Date”)
by and between H-Cyte, Inc., a Nevada corporation (“H-Cyte”), Jantibody, LLC, a Nevada limited liability company (“Jantibody”),
and the members of Jantibody (the “Jantibody Members”). Capitalized terms used herein (including in the immediately
preceding sentence) and not otherwise defined herein shall have the meanings set forth in Section 7.01 hereof.

 

RECITALS

 

WHEREAS,
the parties intend for H-Cyte to acquire membership interests amounting to 100% of the issued and outstanding membership interests of
Jantibody pursuant to Chapter 86 of the Nevada Revised Statutes, as amended from time to time
(the “Act”), and on the terms and subject to the conditions set forth in this Agreement;

 

WHEREAS,
the Board of Managers of Jantibody (the “Jantibody Board”) has unanimously: (a) determined that it is in the best
interests of Jantibody and the Jantibody Members, and declared it advisable, to enter into this Agreement with H-Cyte; (b) approved the
execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby, including the Acquisition;
and (c) resolved, subject to the terms and conditions set forth in this Agreement, to recommend adoption of this Agreement by the Jantibody
Members;

 

WHEREAS,
Jantibody is owned 100% by the Jantibody Members, as identified on Schedule A, who have agreed to the Acquisition and the dollar
value of the Acquisition Consideration that they will individually receive on the terms set forth herein;

 

WHEREAS,
the Board of Directors of H-Cyte (the “H-Cyte Board”) has unanimously: (a) determined that it is in the best interests
of H-Cyte and its respective stockholders, as applicable, and declared it advisable, to enter into this Agreement; and (b) approved the
execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby, including the Acquisition;
and

 

WHEREAS,
the parties desire to make certain representations, warranties, covenants, and agreements in connection with the Acquisition and the
other transactions contemplated by this Agreement and also to prescribe certain terms and conditions to the Acquisition.

 

WHEREAS,
this Agreement contemplates the Acquisition of Jantibody in a transaction intended to qualify as a tax free reorganization under Sections
368(a)(l)(A) and 368(a)(2)(E) of the Internal Revenue Code of 1986, as amended (“Code”).

 

WHEREAS,
on the Closing Date, all Jantibody Members will receive shares of common stock of H-Cyte in exchange for their membership interests in
Jantibody (the “Purchased Interests”), and Jantibody will become a wholly-owned subsidiary of H-Cyte.

 

NOW,
THEREFORE, in consideration of the foregoing and of the representations, warranties, covenants, and agreements contained in this
Agreement, the parties, intending to be legally bound, agree as follows:

 

    	1

     

    

 

ARTICLE
I 

THE
ACQUISITION

 

Section
1.01  The Acquisition. On the terms and subject to the conditions set forth in this Agreement, and in accordance with the Act,
at the Closing, each Jantibody Member will sell, assign, transfer and convey to H-Cyte, and H-Cyte will purchase and acquire from such
Jantibody Member, all right, title and interest of such Jantibody Member in and to that portion of the Purchased Interests owned by such
Jantibody Member representing the Sharing Ratio in Jantibody set forth opposite such Jantibody Member’s name on Schedule A
hereto under the heading “Sharing Ratio Owned” (the “Acquisition”).

 

Section
1.02  Closing. The closing of the Acquisition (the “Closing”) will take place on the date of this Agreement,
or on such other date as Jantibody and H-Cyte may mutually determine. The Closing shall take place remotely by facsimile or electronic
transmissions to the respective offices of the H-Cyte’s and Jantibody’s legal counsel of the requisite documents duly executed
where required, unless another closing procedure is mutually agreed to by Jantibody and H-Cyte in writing. The date on which the Closing
occurs is herein referred to as the “Closing Date”.

 

Section
1.03  Directors and Officers. Jantibody’s officers and managers, in each case, in office immediately prior to the Closing
Date, shall resign, except for Michael W. Yurkowsky, or an individual designated by him who shall remain as a manager of Jantibody. The
total number of managers of Jantibody shall be two (2), and H-Cyte shall designate the second manager of Jantibody.

 

ARTICLE
II 

ACQUISITION
CONSIDERATION

 

Section
2.01  Acquisition Consideration. At the Closing, each Jantibody Member, in consideration for his or its portion of the Purchased
Interests to be sold to and purchased by H-Cyte, shall receive that number of shares of common stock of H-Cyte (“H-Cyte Common
Stock”) set forth opposite such Jantibody Member’s name on Schedule A hereto under the heading “Shares of
H-Cyte Common Stock to be Received” (the “Acquisition Consideration”). On the Closing Date, the shares of H-Cyte
Common Stock comprising the Acquisition Consideration shall be delivered to each Jantibody Member by either (at the election of such
Jantibody Member) (a) book-entry transfer to such account with The Depository Trust Company as is designated in writing by such Jantibody
Member, or (b) a stock certificate registered in the name of such Jantibody Member or its designee. Once the Closing occurs, the Jantibody
Members shall have no further right to the Purchased Interests and shall only have the right to receive the Acquisition Consideration.
The Jantibody Members acknowledge that H-Cyte plans to issue certain other shares of H-Cyte Common Stock that will result in dilution
to the Jantibody Members’ ownership in H-Cyte. In addition, for every share of H-Cyte Common Stock that is issued as a result of
the conversion of any security listed on Schedule B, the Jantibody Members will receive 15% of the aggregate number of shares
issued (the “Anti-Dilution Shares”). The Company commits that they will reconcile the amount of Anti-Dilution Shares
to be issued before the end of each fiscal quarter and to issue any Anti-Dilution Shares at such time.

 

    	2

     

    

 

Section
2.02  Restrictions on Acquisition Consideration; Contingent Shares.

 

(a)
 The Acquisition Consideration shall be subject to the standard securities restriction on trading
during the first six (6) months following the Closing Date. Thereafter, the restriction on trading will be removed on the following schedule:

 

(i) Fifty
percent (50%) of the shares of H-Cyte Common Stock comprising the Acquisition Consideration will be released from any trading restrictions
on the six (6) month anniversary of the Closing Date; and

 

(ii) Fifty
percent (50%) of the shares of H-Cyte Common Stock comprising the Acquisition Consideration will be released from any trading restrictions
on the twelve (12) month anniversary of the Closing Date.

 

(b) Contingent
Shares. In addition to the Acquisition Consideration, the Jantibody Members shall receive additional shares of H-Cyte Common Stock
(the “Contingent Shares”) upon the occurrence of certain conditions. Specifically, Jantibody Members shall receive
the Contingent Shares as follows:

 

		(i)	Upon
                                            the enrollment of the first patient in a Phase I FDA study of any product using or otherwise
                                            incorporating any Jantibody Licensed IP (as defined in Section 3.07(a)), H-Cyte shall issue
                                            to the Jantibody Members (pro rata in accordance with their respective Sharing Ratios set
                                            forth on Schedule A) additional shares of H-Cyte Common Stock equal to 2.0% of the
                                            total number of shares of H-Cyte Common Stock then outstanding on a fully-diluted basis;
                                            and

 

		(ii)	Upon
                                            the enrollment of the first patient in a Phase III FDA study of any product using or otherwise
                                            incorporating any Jantibody Licensed IP, H-Cyte shall issue to the Jantibody Members (pro
                                            rata in accordance with their respective Sharing Ratios set forth on Schedule A) additional
                                            shares of H-Cyte Common Stock equal to 3.0% of the total number of shares of H-Cyte Common
                                            Stock then outstanding on a fully-diluted basis;

 

(c) Full
Satisfaction. All Acquisition Consideration paid upon the Acquisition in accordance with the terms hereof shall be deemed to have
been paid in full satisfaction of all rights pertaining to the Purchased Interests.

 

    	3

     

    

 

Section
2.03  Tax Treatment. The Acquisition is intended to constitute a “reorganization” within the meaning of Section 368(a)
of the Code. The parties hereto intend the Acquisition to constitute a “plan of reorganization” within the meaning of Treasury
Regulations Sections 1.3682(g) and 1.368-3, which plan of reorganization the parties adopt by executing this Agreement. Notwithstanding
the above, H-Cyte is making no representations with regard to the tax free nature of the Acquisition Consideration received therein.

 

ARTICLE
III 

REPRESENTATIONS
AND WARRANTIES OF JANTIBODY

 

Except
as set forth in the correspondingly numbered Section of the Jantibody Disclosure Letter that relates to such Section or in another Section
of the Jantibody Disclosure Letter to the extent that it is reasonably apparent on the face of such disclosure that such disclosure is
applicable to such Section, Jantibody hereby represents and warrants to H-Cyte as follows:

 

Section
3.01  Organization; Standing and Power; Charter Documents; Subsidiaries.

 

(a) Organization;
Standing and Power. Jantibody is a limited liability company duly organized, validly existing, and in good standing (to the extent
that the concept of “good standing” is applicable in the case of any jurisdiction outside the United States) under the Laws
of the State of Nevada, and has the requisite corporate power and authority to own, lease, and operate its assets and to carry on its
business as now conducted. Jantibody is duly qualified or licensed to do business as a foreign limited liability company and is in good
standing (to the extent that the concept of “good standing” is applicable in the case of any jurisdiction outside the United
States) in each jurisdiction where the character of the assets and properties owned, leased, or operated by it or the nature of its business
makes such qualification or license necessary, except where the failure to be so qualified or licensed or to be in good standing, would
not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect. For purposes of this Agreement,
“Laws” means all statutes, laws (including common law and civil law), codes, treaty, ordinances, regulations, rules,
guideline, injunctions, acts or Orders of any Governmental Entity.

 

(b) Charter
Documents. The copies of the Articles of Organization and operating agreement of Jantibody (the “Jantibody Charter Documents”)
in the forms provided to H-Cyte are true, correct, and complete copies of such documents as in effect as of the date of this Agreement.

 

(c) Subsidiaries.
Jantibody has no Subsidiaries. For purposes of this Agreement, “Subsidiary” means, with respect to any Person, any
corporation, limited liability company, partnership, association or other business entity of which (i) if a corporation, a majority of
the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors,
managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries
of that Person or a combination thereof, or (ii) if a limited liability company, partnership, association or other business entity, a
majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by
any Person or one or more Subsidiaries of that Person or a combination thereof and for this purpose, a Person or Persons hold a majority
equity interest in such a business entity (other than a corporation) if such Person or Persons will be allocated a majority of such business
entity’s gains or losses or will be or Control any board of directors, managing director or general partner of such business entity
(other than a corporation) or, in the case of each of clauses (a) and (b), has the power to elect or direct the election of more than
a majority of the members of the governing body of such entity. “Control” means the possession, directly or indirectly,
of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract, or otherwise.

 

    	4

     

    

 

Section
3.02  Capital Structure.

 

(a) Capital
Stock. The membership interests of Jantibody consists of a single class of equity; all of which are issued and outstanding; none
of which is held by Jantibody in its treasury; and all of which are owned by the Jantibody Members as set forth on Schedule A
hereto. All of the outstanding membership interests of Jantibody are duly authorized, validly issued, fully paid, and non-assessable,
and not subject to any pre-emptive rights.

 

(b) Stock
Awards.

 

(i) Jantibody
does not have any equity incentive plans or any outstanding stock options or other stock awards.

 

(ii) As
of the date hereof and other than the Purchased Interests, there are no outstanding: (A) securities of Jantibody convertible into or
exchangeable for Voting Debt or shares of capital stock of Jantibody; (B) options, warrants, or other agreements or commitments to acquire
from Jantibody, or obligations of Jantibody to issue, any Voting Debt or shares of capital stock of (or securities convertible into or
exchangeable for membership interests of) Jantibody; or (C) restricted shares, restricted stock units, stock appreciation rights, performance
shares, profit participation rights, contingent value rights, “phantom” stock, or similar securities or rights that are derivative
of, or provide economic benefits based, directly or indirectly, on the value or price of, any shares of capital stock of Jantibody, in
each case that have been issued by Jantibody (the items in clauses (A), (B), and (C), together with the capital stock of Jantibody, being
referred to collectively as “Jantibody Securities”). All outstanding membership interests of Jantibody have been issued
or granted, as applicable, in compliance in all material respects with all applicable securities Laws.

 

(iii) There
are no outstanding contracts requiring Jantibody to repurchase, redeem, or otherwise acquire any Jantibody Securities. Jantibody is not
a party to any voting agreement with respect to any Jantibody Securities.

 

(c) Voting
Debt. No bonds, debentures, notes, or other indebtedness issued by Jantibody: (i) having the right to vote on any matters on which
Jantibody Members may vote (or which is convertible into, or exchangeable for, securities having such right); or (ii) the value of which
is directly based upon or derived from the capital stock, voting securities, or other ownership interests of Jantibody, are issued or
outstanding (collectively, “Voting Debt”).

 

    	5

     

    

 

Section
3.03 Authority; Non-Contravention; Governmental Consents; Board Approval; Anti-Takeover Statutes.

 

(a) Authority.
Jantibody has all requisite limited liability company power and authority to enter into and to perform its obligations under this Agreement
and, subject to, in the case of the consummation of the Acquisition, adoption of this Agreement by the affirmative vote or consent of
the Jantibody Members who own 100% of the outstanding membership interests of Jantibody (the “Requisite Jantibody Approval”),
to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by Jantibody and the consummation
by Jantibody of the transactions contemplated hereby have been duly authorized by all necessary limited liability company action on the
part of Jantibody and no other limited liability company proceedings on the part of Jantibody are necessary to authorize the execution
and delivery of this Agreement or to consummate the Acquisition and the other transactions contemplated hereby. The Requisite Jantibody
Approval is the only vote or consent of the holders of any class or series of Jantibody’s membership interests necessary to approve
and adopt this Agreement, approve the Acquisition, and consummate the Acquisition and the other transactions contemplated hereby. This
Agreement has been duly executed and delivered by Jantibody and, assuming due execution and delivery by H-Cyte and the Jantibody Members,
constitutes the legal, valid, and binding obligation of Jantibody, enforceable against Jantibody in accordance with its terms, except
as such enforceability may be limited by bankruptcy, insolvency, moratorium, and other similar Laws affecting creditors’ rights
generally and by general principles of equity.

 

(b) Non-Contravention.
The execution, delivery, and performance of this Agreement by Jantibody, and the consummation by Jantibody of the transactions contemplated
by this Agreement, including the Acquisition, do not and will not: (i) subject to obtaining the Requisite Jantibody Approval, contravene
or conflict with, or result in any violation or breach of, the Jantibody Charter Documents; (ii) assuming that all Consents contemplated
by Section 3.03(c) have been obtained or made and, in the case of the consummation of the Acquisition, obtaining the Requisite Jantibody
Approval, conflict with or violate any Law applicable to Jantibody, or any of its properties or assets; (iii) result in any breach of
or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in Jantibody’s
loss of any benefit or the imposition of any additional payment or other Liability under, or alter the rights or obligations of any third
party under, or give to any third party any rights of termination, amendment, acceleration, or cancellation, or require any Consent under,
any contract to which Jantibody is a party or otherwise bound as of the date hereof; or (iv) result in the creation of any liens, restrictions,
security interests, claims, rights of another or other encumbrances (collectively, “Liens”) (other than Permitted
Liens, as defined below) on any of the properties or assets of Jantibody, except, in the case of each of clauses (ii), (iii), and (iv),
for any conflicts, violations, breaches, defaults, loss of benefits, additional payments or other liabilities, alterations, terminations,
amendments, accelerations, cancellations, or Liens that, or where the failure to obtain any Consents, in each case, would not reasonably
be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect. For purposes of this Agreement, (A) “Liability”
means, with respect to any Person, any liability or obligation of such Person, whether known or unknown, whether asserted or unasserted,
whether determined, determinable or otherwise, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated,
whether due or to become due, and whether or not required under generally accepted accounting principles (“GAAP”)
to be accrued on the financial statements of such Person, and (B) “Permitted Liens” means (1) statutory Liens for
current Taxes (as defined below) or other governmental charges not yet due and payable or the amount or validity of which is being contested
in good faith by appropriate proceedings by Jantibody, (2) mechanic’s, carriers’, workers’, repairers’ and similar
statutory Liens arising or incurred in the ordinary course of business for amounts which are not delinquent and which are not, individually
or in the aggregate, significant, (3) Liens arising under worker’s compensation, unemployment insurance, social security, retirement
and similar legislation, and (4) restrictions on transfer under the Jantibody Charter Documents or applicable federal and state securities
Laws.

 

    	6

     

    

 

(c) Governmental
Consents. No consent, approval, order, or authorization of, or registration, declaration, or filing with, or notice to (any of the
foregoing being a “Consent”), any supranational, national, state, municipal, local, or foreign government, any instrumentality,
subdivision, court, administrative agency or commission, or other governmental authority, or any quasi-governmental or private body exercising
any regulatory or other governmental or quasi-governmental authority (a “Governmental Entity”) is required to be obtained
or made by Jantibody in connection with the execution, delivery, and performance by Jantibody of this Agreement or the consummation by
Jantibody of the Acquisition and other transactions contemplated hereby, except for such Consents which if not obtained or made would
not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect.

 

(d) Board
Approval. The managers of Jantibody, by resolution and, not subsequently rescinded or modified in any way, have: (i) determined that
this Agreement and the transactions contemplated hereby, including the Acquisition, upon the terms and subject to the conditions set
forth herein, are fair to, and in the best interests of, Jantibody and the Jantibody Members; (ii) approved and declared advisable this
Agreement, including the execution, delivery, and performance thereof, and the consummation of the transactions contemplated by this
Agreement, including the Acquisition, upon the terms and subject to the conditions set forth herein.

 

(e) Anti-Takeover
Statutes. No “fair price,” “moratorium,” “control share acquisition,” “supermajority,”
“affiliate transactions,” “business combination,” or other similar anti-takeover statute or regulation enacted
under any federal, state, local, or foreign Laws applicable to Jantibody is applicable to this Agreement, the Acquisition, or any of
the other transactions contemplated by this Agreement.

 

    	7

     

    

 

Section
3.04 Financial Statements; Off-Balance Sheet Arrangements; Undisclosed Liabilities.

 

(a) Financial
Statements. Jantibody has provided H-Cyte with an internally prepared balance sheet of Jantibody as of April 30, 2022 (the “Interim
Balance Sheet”), and the related profit and loss statement of Jantibody for the four-month period then ended. Such financial
statements (i) fairly present in all material respects the financial position and the results of operations of Jantibody as of the respective
date of and for the period referred to in such financial statements, subject to the lack of footnote disclosures and changes resulting
from normal and customary year-end adjustments, and (ii) are to Jantibody’s knowledge in a form that will be auditable by H-Cyte’s
auditors.

 

(b) Off-Balance
Sheet Arrangements. Jantibody is not a party to, or has any commitment to become a party to: (i) any joint venture, off-balance sheet
partnership, or any similar Contract or arrangement (including any Contract or arrangement relating to any transaction or relationship
between or among Jantibody or any of its Subsidiaries, on the one hand, and any other Person, including any structured finance, special
purpose, or limited purpose Person, on the other hand); or (ii) any “off-balance sheet arrangements” (as defined in Item
303(a) of Regulation S-K under the Exchange Act). For purposes of this Agreement, (i) “Person” means a natural individual,
a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, a bank, a
trust company, an unincorporated organization and a Governmental Entity or any department, agency or political subdivision thereof, and
(ii) “Contract” means any contract, agreement, indenture, mortgage, debenture, note, instrument, consent, lease, license,
release, covenant not to sue, understanding, arrangement or commitment, written or oral, to which Jantibody is a party or by which Jantibody
or any of its properties, rights or assets are bound.

 

(c) Undisclosed
Liabilities. Except as disclosed in Schedule 3.04(c) of the Jantibody Disclosure Letter, Jantibody does not have any Liabilities
other than Liabilities that: (i) are reflected or reserved against in the Interim Balance Sheet; (ii) were incurred since the date of
the Interim Balance Sheet in the ordinary course of business consistent with past practice; (iii) are incurred in connection with the
transactions contemplated by this Agreement; (iv) would not reasonably be expected to have, individually or in the aggregate, a Jantibody
Material Adverse Effect; or (v) were assumed from AperiSys, Inc., a Florida corporation (“AperiSys”), pursuant to
that certain Asset Purchase Agreement, dated June 1, 2022, by and between Jantibody and AperiSys.

 

Section
3.05 Absence of Certain Changes or Events. Since April 30, 2022, except in connection with the execution and delivery of this
Agreement and the consummation of the transactions contemplated hereby, the business of Jantibody has been conducted in the ordinary
course of business consistent with past practice and there has not been or occurred:

 

(a) any
Jantibody Material Adverse Effect or any event, condition, change, or effect that could reasonably be expected to have, individually
or in the aggregate, a Jantibody Material Adverse Effect; or

 

(b) any
event, condition, action, or effect that, if taken during the period from the date of this Agreement through the Closing Date, would
constitute a breach of Section 6.01.

 

    	8

     

    

 

Section
3.06 Taxes.

 

(a) Tax
Returns and Payment of Taxes. Jantibody has duly and timely filed or caused to be filed (taking into account any valid extensions)
all material Tax Returns required to be filed by it. Such Tax Returns are true, complete, and correct in all material respects. Jantibody
is not currently the beneficiary of any extension of time within which to file any Tax Return other than extensions of time to file Tax
Returns obtained in the ordinary course of business consistent with past practice. All material Taxes due and owing by Jantibody (whether
or not shown on any Tax Return) have been timely paid or, where payment is not yet due, Jantibody has made an adequate provision for
such Taxes in Jantibody’s financial statements (in accordance with GAAP). Jantibody’s most recent financial statements reflect
an adequate reserve (in accordance with GAAP) for all material Taxes payable by Jantibody through the date of such financial statements.
Jantibody has not incurred any material Liability for Taxes since the date of Jantibody’s most recent financial statements outside
of the ordinary course of business or otherwise inconsistent with past practice.

 

(b) Availability
of Tax Returns. Jantibody has made available to H-Cyte complete and accurate copies of all Tax Returns filed by or on behalf of Jantibody
for any Tax period ending after December 31, 2020.

 

(c) Withholding.
Jantibody has withheld and timely paid each material Tax required to have been withheld and paid in connection with amounts paid or owing
to any Jantibody Employee, creditor, customer, stockholder, or other party (including, without limitation, withholding of Taxes pursuant
to Sections 1441 and 1442 of the Code or similar provisions under any state, local, and foreign Laws), and materially complied with all
information reporting and backup withholding provisions of applicable Law.

 

(d) Liens.
There are no Liens for material Taxes upon the assets of Jantibody other than for current Taxes not yet due and payable or for Taxes
that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP has been made
in Jantibody’s most recent financial statements.

 

(e) Tax
Deficiencies and Audits. No deficiency for any material amount of Taxes which has been proposed, asserted, or assessed in writing
by any taxing authority against Jantibody remains unpaid. There are no waivers or extensions of any statute of limitations currently
in effect with respect to Taxes of Jantibody. There are no audits, suits, proceedings, investigations, claims, examinations, or other
administrative or judicial proceedings ongoing or pending with respect to any material Taxes of Jantibody.

 

    	9

     

    

 

(f) Tax
Jurisdictions. No claim has ever been made in writing by any taxing authority in a jurisdiction where Jantibody does not file Tax
Returns that Jantibody is or may be subject to Tax in that jurisdiction.

 

(g) Tax
Rulings. Jantibody has not requested nor is it the subject of or bound by any private letter ruling, technical advice memorandum,
or similar ruling or memorandum with any taxing authority with respect to any material Taxes, nor is any such request outstanding.

 

(h) Consolidated
Groups, Transferee Liability, and Tax Agreements. Jantibody has not: (i) been a member of a group filing Tax Returns on a consolidated,
combined, unitary, or similar basis; (ii) incurred any material Liability for Taxes of any Person (other than Jantibody) under Treasury
Regulation Section 1.1502-6 (or any comparable provision of local, state, or foreign Law), as a transferee or successor, by Contract,
or otherwise; or (iii) is a party to, bound by or has any material Liability under any Tax sharing, allocation, or indemnification agreement
or arrangement (other than customary Tax indemnifications contained in credit or other commercial agreements the primary purpose of which
agreements does not relate to Taxes).

 

(i) Change
in Accounting Method. Jantibody has not agreed to make, nor is it required to make, any material adjustment under Section 481(a)
of the Code or any comparable provision of state, local, or foreign Tax Laws by reason of a change in accounting method or otherwise.

 

(j) Post-Closing
Tax Items. Jantibody will not be required to include any material item of income in, or exclude any material item of deduction from,
taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i) “closing agreement”
as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law) executed
on or prior to the Closing Date; (ii) installment sale or open transaction disposition made on or prior to the Closing Date; (iii) prepaid
amount received on or prior to the Closing Date; (iv) any income under Section 965(a) of the Code, including as a result of any election
under Section 965(h) of the Code with respect thereto; or (v) election under Section 108(i) of the Code.

 

(k) Section
355. Jantibody has not been a “distributing corporation” or a “controlled corporation” in connection with
a distribution described in Section 355 of the Code.

 

(l) Reportable
Transactions. Jantibody has not been a party to, or a material advisor with respect to, a “reportable transaction” within
the meaning of Section 6707AI(1) of the Code and Treasury Regulations Section 1.6011-4(b).

 

    	10

     

    

 

(m) Definitions.
For purposes of this Agreement, (i) “Tax” or “Taxes” means federal, state, county, local, foreign
or other income, gross receipts, ad valorem, franchise, profits, sales or use, transfer, registration, excise, utility, environmental,
communications, real or personal property, escheat, unclaimed property, capital stock, license, payroll, wage or other withholding, employment,
social security, severance, stamp, occupation, alternative or add-on minimum, estimated, and other taxes, fees, tariffs, duties, charges,
levies or assessments of any kind whatsoever (including deficiencies, penalties, additions to tax, and interest attributable thereto),
whether disputed or not and whether payable directly or by withholding, and including any Liability for the payment of any such amount
as a result of being or having been a member of an affiliated, consolidated, combined or unitary group, successor or transferor Liability,
contract, operation of Law or otherwise, and (ii) “Tax Return” means any return, declarations, reports, claims for
refunds, statements, information report or other documents with respect to Taxes that are filed or required to be filed, or provided
or required to be provided to a payee, including any schedules attached thereto and including any amendment thereof.

 

Section
3.07 Intellectual Property.

 

(a) Intellectual
Property Rights. Jantibody does not directly own any material Intellectual Property. Section 3.07(a) of the Jantibody Disclosure
Letter contains a true and complete list, as of the date hereof, of all Intellectual Property in which Jantibody has any material right,
license or interest (the “Jantibody Licensed IP”). For purposes of this Agreement, “Intellectual Property”
means all rights in or affecting intellectual or industrial property or other proprietary rights existing now or in the future in any
jurisdiction, including with respect of the following: (i) all patents and applications therefor, including continuations, divisionals,
continuations-in-part, or reissues of patent applications and patents issuing thereon, including the right to file other or further applications
and claim priority thereto, (ii) all trademarks, service marks, trade names, service names, brand names and trade dress rights, and all
applications, registrations and renewals thereof, (iii) copyrights and registrations and applications therefor, works of authorship,
“moral” rights and mask work rights, (iv) domain names, uniform resource locators and other names and locators associated
with the internet, including applications and registrations thereof, (v) trademarks, trade dress, trade names, logos and service marks,
together with the goodwill symbolized by or associated with any of the foregoing and any applications and registrations therefor, (vi)
all proprietary information and materials, whether or not patentable or copyrightable, and whether or not reduced to practice, including
all technology, ideas, research and development, inventions, designs, manufacturing and operating specifications and processes, schematics,
know-how, formulae, customer and supplier lists, shop rights, designs, drawings, patterns, trade secrets, confidential information, technical
data, databases, data compilations and collections, web addresses and sites, software, architecture, and documentation, (vii) all other
intangible assets, properties and rights, and (viii) all claims, causes of action and rights to sue for past, present and future infringement
of any of the foregoing, the right to file applications and obtain registrations, all copies and tangible embodiments of any of the foregoing
(in whatever form or medium), and all proceeds, rights of recovery and revenues arising from or pertaining to any and all of the foregoing.

 

    	11

     

    

 

(b) Right
to Use; Title. Except for any integrated third party Intellectual Property subject to a valid licensing agreement as set forth in
Schedule 3.07(b), Jantibody has the valid and enforceable right to use all Jantibody Licensed IP, in each case, free and clear of all
Liens other than Permitted Liens, except as would not reasonably be expected to have, individually or in the aggregate, a Jantibody Material
Adverse Effect.

 

(c) Validity
and Enforceability. Jantibody’s rights, to and in Jantibody Licensed IP are valid, subsisting, and enforceable, except as would
not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect. Jantibody has taken reasonable
steps to maintain Jantibody Licensed IP and to protect and preserve the confidentiality of all trade secrets included in Jantibody Licensed
IP, except where the failure to take such actions would not reasonably be expected to have, individually or in the aggregate, a Jantibody
Material Adverse Effect.

 

(d) Non-Infringement.
Except as would not be reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect: (i) to
the conduct of the businesses of Jantibody has not infringed, misappropriated, or otherwise violated, and is not infringing, misappropriating,
or otherwise violating, any Intellectual Property of any other Person; and (ii) to the knowledge of Jantibody, no third party is infringing
upon, violating, or misappropriating any Jantibody Licensed IP.

 

(e) IP
Legal Actions and Orders. There are no Legal Actions pending or, to the knowledge of Jantibody, threatened: (i) alleging any infringement,
misappropriation, or violation by Jantibody of the Intellectual Property of any Person; or (ii) challenging the validity, enforceability,
or ownership of any Jantibody Licensed IP or Jantibody’s rights with respect to any Jantibody Licensed IP, in each case except
for such Legal Actions that would not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse
Effect. Jantibody is not subject to any outstanding Order that restricts or impairs the use of any Jantibody Licensed IP, except where
compliance with such Order would not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect.

 

(f) Privacy
and Data Security. Jantibody, to its best of knowledge, has complied in all material respects with all applicable Laws and all internal
or publicly posted policies, notices, and statements concerning the collection, use, processing, storage, transfer, and security of personal
information in the conduct of Jantibody’s businesses, in each case except as would not reasonably be expected to have, individually
or in the aggregate, a Jantibody Material Adverse Effect. In the past twelve (12) months, Jantibody has not: (i) experienced any actual,
alleged, or suspected data breach or other security incident involving personal information in their possession or control; or (ii) been
subject to or received any notice of any audit, investigation, complaint, or other Legal Action by any Governmental Entity or other Person
concerning Jantibody’s collection, use, processing, storage, transfer, or protection of personal information or actual, alleged,
or suspected violation of any applicable Law concerning privacy, data security, or data breach notification, and there are no facts or
circumstances that could reasonably be expected to give rise to any such Legal Action, in each case except as would not reasonably be
expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect.

 

    	12

     

    

 

Section
3.08 Compliance; Permits.

 

(a) Compliance.
Jantibody is and, since January 1, 2021, has been in material compliance with all Laws or Orders applicable to Jantibody or by which
Jantibody or any of its businesses or properties is bound. Since January 1, 2021, no Governmental Entity, including the U.S. food drug
administration (“FDA”), has issued any notice or notification stating that Jantibody is not in compliance with any
Law in any material respect.

 

(b) Permits.
Jantibody holds and, to the extent necessary to operate its businesses as such businesses are being operated as of the date hereof, all
permits, licenses, registrations, variances, clearances, consents, commissions, franchises, exemptions, Orders, authorizations, and approvals
from Governmental Entities (collectively, “Permits”), except for any Permits for which the failure to obtain or hold
would not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect (the “Excluded
Permits”). Schedule 3.08(b) of the Jantibody Disclosure Letter contains a complete and accurate list of the Permits (except
any Excluded Permits). No suspension, cancellation, non-renewal, or adverse modifications of any Permits of Jantibody is pending or,
to the knowledge of Jantibody, threatened, except for any such suspension or cancellation which would not reasonably be expected to have,
individually or in the aggregate, a Jantibody Material Adverse Effect. Jantibody is and, since January 1, 2021, has been in compliance
with the terms of all Permits, except where the failure to be in such compliance would not reasonably be expected to have, individually
or in the aggregate, a Jantibody Material Adverse Effect.

 

Section
3.09 Litigation. Except as disclosed in Schedule 3.09 of the Jantibody Disclosure Letter, there is no Legal Action pending, or
to the knowledge of Jantibody, threatened against Jantibody or any of its properties or assets or, to the knowledge of Jantibody, any
officer or director of Jantibody in his or her capacities as such other than any such Legal Action that: (a) does not involve an amount
in controversy in excess of $50,000; and (b) does not seek material injunctive or other material nonmonetary relief. Notwithstanding
the $50,000 threshold, each Legal Action which Jantibody is a party to and which would reasonably be expected to have a Jantibody Material
Adverse Effect, is disclosed in Schedule 3.09. None of Jantibody or any of its properties or assets is subject to any order, writ, assessment,
decision, injunction, decree, ruling, or judgment of a Governmental Entity or arbitrator, whether temporary, preliminary, or permanent
(“Order”), which would reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse
Effect. To the knowledge of Jantibody, there are no SEC inquiries or investigations, other governmental inquiries or investigations,
or internal investigations pending or, to the knowledge of Jantibody, threatened, in each case regarding any accounting practices of
Jantibody or any malfeasance by any officer or director of Jantibody. For purposes of this Agreement, “Legal Action”
means any action, lawsuit, proceeding (including any arbitration proceedings), investigation, audit, examination, Order, or other claim.

 

    	13

     

    

 

Section
3.10 Brokers’ and Finders’ Fees. Other than as set forth in Section 3.10 of the Jantibody Disclosure Letter, Jantibody
has not incurred, nor will it incur, directly or indirectly, any other Liability for investment banker, brokerage, or finders’
fees or agents’ commissions, or any similar charges in connection with this Agreement or any transaction contemplated by this Agreement.
Any such fees, commissions or charges shall be a Liability of the Jantibody Members out of the Acquisition Consideration and shall not
be the responsibility of Jantibody or H-Cyte.

 

Section
3.11 Employee Benefit Issues.

 

(a) Schedule.
Section 3.11(a) of the Jantibody Disclosure Letter contains a true and complete list, as of the date hereof, of each plan, program, policy,
agreement, collective bargaining agreement, or other arrangement providing for compensation, severance, deferred compensation, performance
awards, stock or stock-based awards, health, dental, retirement, life insurance, death, accidental death & dismemberment, disability,
fringe, or wellness benefits, or other employee benefits or remuneration of any kind, including each employment, termination, severance,
retention, change in control, or consulting or independent contractor plan, program, arrangement, or agreement, in each case whether
written or unwritten or otherwise, funded or unfunded, insured or self-insured, including each “employee benefit plan,” within
the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974 (“ERISA”), whether or not subject
to ERISA, which is or has been sponsored, maintained, contributed to, or required to be contributed to, by Jantibody for the benefit
of any current or former employee, independent contractor, consultant, or director of Jantibody (each, a “Jantibody Employee”),
or with respect to which Jantibody or any corporation, partnership, limited liability company, sole proprietorship, trade, business or
other Person that, together with Jantibody, is or, at any time, was treated as a single employer under Section 414(b), (c), (m) or (o)
of the Code or Section 4001(a)(14) or 4001(b)(1) of ERISA (each, a “Jantibody ERISA Affiliate”) has or may have any
Liability (collectively, the “Jantibody Employee Plans”).

 

(b) Documents.
Jantibody has made available to H-Cyte, as applicable, correct and complete copies (or, if a plan or arrangement is not written, a written
description) of all Jantibody Employee Plans and amendments thereto, and, to the extent applicable: (i) all related trust agreements,
funding arrangements, insurance contracts, and service provider agreements now in effect or required in the future as a result of the
transactions contemplated by this Agreement or otherwise; (ii) the most recent determination letter received regarding the tax-qualified
status of each Jantibody Employee Plan; (iii) the most recent financial statements for each Jantibody Employee Plan; (iv) the Form 5500
Annual Returns/Reports and Schedules for the most recent plan year for each Jantibody Employee Plan; (v) the current summary plan description
and any related summary of material modifications and, if applicable, summary of benefits and coverage, for each Jantibody Employee Plan;
and (vi) all actuarial valuation reports related to any Jantibody Employee Plans.

 

    	14

     

    

 

(c) Employee
Plan Compliance. (i) Each Jantibody Employee Plan has been established, administered, and maintained in all material respects in
accordance with its terms and in material compliance with applicable Laws, including but not limited to ERISA and the Code; (ii) all
Jantibody Employee Plans that are intended to be qualified under Section 401(a) of the Code are so qualified and have received timely
determination letters from the United States Internal Revenue Service (the “IRS”) and no such determination letter
has been revoked nor, to the knowledge of Jantibody, has any such revocation been threatened, or with respect to a prototype plan, can
rely on an opinion letter from the IRS to the prototype plan sponsor, to the effect that such qualified retirement plan and the related
trust are exempt from federal income taxes under Sections 401(a) and 501(a), respectively, of the Code, and to the knowledge of Jantibody
no circumstance exists that is likely to result in the loss of such qualified status under Section 401(a) of the Code; (iii) Jantibody,
as applicable, has timely made all contributions, benefits, premiums, and other payments required by and due under the terms of each
Jantibody Employee Plan and applicable Law and accounting principles, and all benefits accrued under any unfunded Jantibody Employee
Plan have been paid, accrued, or otherwise adequately reserved to the extent required by, and in accordance with GAAP; (iv) except to
the extent limited by applicable Law, each Jantibody Employee Plan can be amended, terminated, or otherwise discontinued after the Closing
Date in accordance with its terms, without material Liability to H-Cyte or Jantibody (other than ordinary administration expenses and
in respect of accrued benefits thereunder); (v) there are no investigations, audits, inquiries, enforcement actions, or Legal Actions
pending or, to the knowledge of Jantibody, threatened by the IRS, U.S. Department of Labor, Health and Human Services, Equal Employment
Opportunity Commission, or any similar Governmental Entity with respect to any Jantibody Employee Plan; (vi) there are no material Legal
Actions pending, or, to the knowledge of Jantibody, threatened with respect to any Jantibody Employee Plan (in each case, other than
routine claims for benefits); (vii) to the knowledge of Jantibody, neither Jantibody nor any of its Jantibody ERISA Affiliates has engaged
in a transaction that could subject Jantibody or any Jantibody ERISA Affiliate to a tax or penalty imposed by either Section 4975 of
the Code or Section 502(i) of ERISA; and (viii) all non-U.S. Jantibody Employee Plans that are intended to be funded or book-reserved
are funded or book-reserved, as appropriate, based on reasonable actuarial assumptions.

 

(d) Plan
Liabilities. Neither Jantibody nor any Jantibody ERISA Affiliate has: (i) incurred or reasonably expects to incur, either directly
or indirectly, any Liability under Title I or Title IV of ERISA, or related provisions of the Code or foreign Law relating to any Jantibody
Employee Plan and nothing has occurred that could reasonably be expected to constitute grounds under Title IV of ERISA to terminate,
or appoint a trustee to administer, any Jantibody Employee Plan; (ii) except for payments of premiums to the Pension Benefit Guaranty
Corporation (“PBGC”) which have been timely paid in full, not incurred any Liability to the PBGC in connection with
any Jantibody Employee Plan covering any active, retired, or former employees or directors of Jantibody or any Jantibody ERISA Affiliate,
including, without limitation, any Liability under Sections 4069 or 4212(c) of ERISA or any penalty imposed under Section 4071 of ERISA,
or ceased operations at any facility, or withdrawn from any such Jantibody Employee Plan in a manner that could subject it to Liability
under Sections 4062, 4063 or 4064 of ERISA; (iii) failed to satisfy the health plan compliance requirements under the Affordable Care
Act, including the employer mandate under Section 4980H of the Code and related information reporting requirements; (iv) failed to comply
with Sections 601 through 608 of ERISA and Section 4980B of the Code, regarding the health plan continuation coverage requirements under
the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”);
(v) failed to comply with the privacy, security, and breach notification requirements under the
Health Insurance Portability and Accountability Act of 1996 (“HIPAA”); or (vi) incurred any withdrawal Liability
(including any contingent or secondary withdrawal Liability) within the meaning of Sections 4201 or 4204 of ERISA to any multiemployer
plan and nothing has occurred that presents a material risk of the occurrence of any withdrawal from or the partition, termination, reorganization,
or insolvency of any such multiemployer plan which could result in any Liability of Jantibody or any Jantibody ERISA Affiliate to any
such multiemployer plan. No complete or partial termination of any Jantibody Employee Plan has occurred or is expected to occur.

 

    	15

     

    

 

(e) Certain
Jantibody Employee Plans. With respect to each Jantibody Employee Plan:

 

(i) no
such plan is a “multiemployer plan” within the meaning of Section 3(37) of ERISA or a “multiple employer plan”
within the meaning of Section 413(c) of the Code and neither Jantibody nor any of its Jantibody ERISA Affiliates has now or at any time
within the previous six years contributed to, sponsored, maintained, or had any Liability or obligation in respect of any such multiemployer
plan or multiple employer plan;

 

(ii) no
Legal Action has been initiated by the PBGC to terminate any such Jantibody Employee Plan or to appoint a trustee for any such Jantibody
Employee Plan;

 

(iii) no
Jantibody Employee Plan is subject to the minimum funding standards of Section 302 of ERISA or Sections 412, 418(b), or 430 of the Code,
and none of the assets of Jantibody or any Jantibody ERISA Affiliate is, or may reasonably be expected to become, the subject of any
lien arising under Section 303 of ERISA or Sections 430 or 436 of the Code; and

 

(iv) no
“reportable event,” as defined in Section 4043 of ERISA, has occurred, or is reasonably expected to occur, with respect to
any such Jantibody Employee Plan.

 

(f) No
Post-Employment Obligations. No Jantibody Employee Plan provides post-termination or retiree health benefits to any person for any
reason, except as may be required by COBRA or other applicable Law, and neither Jantibody nor any Jantibody ERISA Affiliate has any Liability
to provide post-termination or retiree health benefits to any person or ever represented, promised, or contracted to any Jantibody Employee
(either individually or to Jantibody Employees as a group) or any other person that such Jantibody Employee(s) or other person would
be provided with post-termination or retiree health benefits, except to the extent required by COBRA or other applicable Law.

 

    	16

     

    

 

(g) Potential
Governmental or Lawsuit Liability. Other than routine claims for benefits: (i) there are no pending or, to the knowledge of Jantibody,
threatened claims by or on behalf of any participant in any Jantibody Employee Plan, or otherwise involving any Jantibody Employee Plan
or the assets of any Jantibody Employee Plan; and (ii) no Jantibody Employee Plan is presently or has within the three years prior to
the date hereof, been the subject of an examination or audit by a Governmental Entity or is the subject of an application or filing under,
or is a participant in, an amnesty, voluntary compliance, self-correction, or similar program sponsored by any Governmental Entity.

 

(h) Section
409A Compliance. Each Jantibody Employee Plan that is subject to Section 409A of the Code has been operated in compliance with such
section and all applicable regulatory guidance (including, without limitation, proposed regulations, notices, rulings, and final regulations).

 

(i) Health
Plan Compliance. Jantibody complies in all material respects with the applicable requirements under ERISA and the Code, including
COBRA, HIPAA, and the Affordable Care Act, and other federal requirements for employer-sponsored health plans, and any corresponding
requirements under state statutes, with respect to each Jantibody Employee Plan that is a group health plan within the meaning of Section
733(a) of ERISA, Section 5000(b)(1) of the Code, or such state statute.

 

(j) Effect
of Transaction. Neither the execution or delivery of this Agreement, the consummation of the Acquisition, nor any of the other transactions
contemplated by this Agreement will (either alone or in combination with any other event): (i) entitle any current or former director,
employee, contractor, or consultant of Jantibody to severance pay or any other payment; (ii) accelerate the timing of payment, funding,
or vesting, or increase the amount of compensation due to any such individual; (iii) limit or restrict the right of Jantibody to merge,
amend, or terminate any Jantibody Employee Plan; or (iv) increase the amount payable or result in any other material obligation pursuant
to any Jantibody Employee Plan. No amount that could be received (whether in cash or property or the vesting of any property) as a result
of the consummation of the transactions contemplated by this Agreement by any employee, director, or other service provider of Jantibody
under any Jantibody Employee Plan or otherwise would not be deductible by reason of Section 280G of the Code nor would be subject to
an excise tax under Section 4999 of the Code.

 

(k) Employment
Law Matters. Jantibody to its best of knowledge: (i) is in compliance with all applicable Laws and agreements regarding hiring, employment,
termination of employment, plant closing and mass layoff, employment discrimination, harassment, retaliation, and reasonable accommodation,
leaves of absence, terms and conditions of employment, wages and hours of work, employee classification, employee health and safety,
use of genetic information, leasing and supply of temporary and contingent staff, engagement of independent contractors, including proper
classification of same, payroll taxes, and immigration with respect to Jantibody Employees and contingent workers; and (ii) is in compliance
with all applicable Laws relating to the relations between it and any labor organization, trade union, work council, or other body representing
Jantibody Employees, except, in the case of clauses (i) and (ii) immediately above, where the failure to be in compliance with the foregoing
would not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect.

 

    	17

     

    

 

(l) Labor.
Jantibody is not party to, or subject to, any collective bargaining agreement or other agreement with any labor organization, work council,
or trade union with respect to any of its or their operations. No material work stoppage, slowdown, or labor strike against Jantibody
with respect to employees who are employed within the United States is pending, threatened, or has occurred in the last two years, and,
to the knowledge of Jantibody, no material work stoppage, slowdown, or labor strike against Jantibody with respect to employees who are
employed outside the United States is pending, threatened, or has occurred in the last two years. None of the Jantibody’s Employees
is represented by a labor organization, work council, or trade union and, to the knowledge of Jantibody, there is no organizing activity,
Legal Action, election petition, union card signing or other union activity, or union corporate campaigns of or by any labor organization,
trade union, or work council directed at Jantibody, or any Jantibody Employees. There are no Legal Actions, government investigations,
or labor grievances pending, or, to the knowledge of Jantibody, threatened relating to any employment related matter involving any Jantibody
Employee or applicant, including, but not limited to, charges of unlawful discrimination, retaliation or harassment, failure to provide
reasonable accommodation, denial of a leave of absence, failure to provide compensation or benefits, unfair labor practices, or other
alleged violations of Law, except for any of the foregoing which would not reasonably be expected to have, individually or in the aggregate,
a Jantibody Material Adverse Effect.

 

Section
3.12 Real Property and Personal Property Matters.

 

(a) Owned
Real Estate. Jantibody does not own any land, buildings, structures, improvements, fixtures or other interest in real property (“Real
Estate”).

 

(b) Leased
Real Estate. Jantibody does not lease any Real Estate.

 

(c) Personal
Property. Except as would not reasonably be expected to have, individually or in the aggregate, a Jantibody Material Adverse Effect,
Jantibody is in possession of and have good and marketable title to, or valid leasehold interests in or valid rights under contract to
use, the machinery, equipment, furniture, fixtures, and other tangible personal property and assets owned, leased, or used by Jantibody,
free and clear of all Liens other than Permitted Liens.

 

    	18

     

    

 

Section
3.13 Environmental Matters. Except for such matters as would not reasonably be expected to have, individually or in the aggregate,
a Jantibody Material Adverse Effect:

 

(a)
 Compliance with Environmental Laws. Jantibody is, and has been, in compliance with all
Environmental Laws, which compliance includes the possession, maintenance of, compliance with, or application for, all Permits required
under applicable Environmental Laws for the operation of the business of Jantibody as currently conducted. For purposes of this Agreement,
“Environmental Laws” means all Laws relating to protection of human health or the environment (including ambient air,
surface water, ground water, drinking water, wildlife, plants, land surface or subsurface strata), including Laws relating to (i) the
presence of, or releases or threatened releases of, Hazardous Substances; (ii) the generation, manufacture, processing, distribution,
use, treatment, storage, disposal, transport, handling, distribution, import, export, labeling, recycling, registration, investigation,
removal, cleanup or remediation of Hazardous Substances or documentation related to the foregoing; (iii) the transfer of interest in
or control of Real Estate that may be contaminated; (iv) community or worker right-to-know disclosures with respect to Hazardous Substances;
(v) the protection of wildlife, marine life and wetlands, and endangered or threatened species; (vi) storage tanks, vessels, containers,
abandoned or discarded barrels or other closed receptacles containing Hazardous Substances; (vii) health and safety of employees or other
persons; or (viii) otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling
of Hazardous Substances.

 

(b)
 No Disposal, Release, or Discharge of Hazardous Substances. Jantibody has not disposed
of, released, or discharged any Hazardous Substances on, at, under, in, or from any Real Estate currently or, to the knowledge of Jantibody,
formerly owned, leased, or operated by it or at any other location that is: (i) currently subject to any investigation, remediation,
or monitoring; or (ii) reasonably likely to result in Liability to Jantibody, in either case of (i) or (ii) under any applicable Environmental
Laws. For purposes of this Agreement, “Hazardous Substances” means: (A) any petroleum or petroleum products, radioactive
materials, asbestos in any form, mold, mildew, urea formaldehyde foam insulation, transformers or other equipment that contain dielectric
fluid containing regulated levels of polychlorinated biphenyls (PCBs) and radon gas; and (B) any chemicals, materials or substances that
are now or ever have been defined as or included in the definition of “hazardous substances,” “hazardous wastes,”
“hazardous materials,” “extremely hazardous wastes,” “restricted hazardous wastes,” “toxic
substances,” “toxic pollutants,” or other words of similar import, under any Environmental Law.

 

(c) No
Production or Exposure of Hazardous Substances. Jantibody has not: (i) produced, processed, manufactured, generated, transported,
treated, handled, used, or stored any Hazardous Substances, except in compliance with Environmental Laws, at any Real Estate; or (ii)
exposed any employee or any third party to any Hazardous Substances under circumstances reasonably expected to give rise to any material
Liability or obligation under any Environmental Law.

 

(d) No
Legal Actions or Orders. Jantibody has not received written notice of and there is no Legal Action pending, or to the knowledge of
Jantibody, threatened against Jantibody, alleging any Liability or responsibility under or non-compliance with any Environmental Law
or seeking to impose any financial responsibility for any investigation, cleanup, removal, containment, or any other remediation or compliance
under any Environmental Law. Jantibody is not subject to any Order, settlement agreement, or other written agreement by or with any Governmental
Entity or third party imposing any material Liability or obligation with respect to any of the foregoing.

 

    	19

     

    

 

(e) No
Assumption of Environmental Law Liabilities. Jantibody has not expressly assumed or retained any Liabilities under any applicable
Environmental Laws of any other Person, including in any acquisition or divestiture of any property or business.

 

Section
3.14 Material Contracts.

 

(a) Material
Contracts. For purposes of this Agreement, “Jantibody Material Contract” shall mean the following to which Jantibody
is a party or any of the respective assets are bound (excluding any leases):

 

(i) any
“material contract” (as such term is defined in Item 601(b)(10) of Regulation S-K of the Securities Act of 1933, as amended);

 

(ii) any
employment or consulting Contract (in each case with respect to which Jantibody has continuing obligations as of the date hereof) with
any current or former (A) officer of Jantibody, (B) member of the Jantibody Board, or (C) Jantibody Employee providing for an annual
base salary or payment in excess of $60,000;

 

(iii) any
Contract providing for indemnification or any guaranty by Jantibody, in each case that is material to Jantibody, taken as a whole, other
than (A) any guaranty by Jantibody thereof of any of the obligations of Jantibody, or (B) any Contract providing for indemnification
of customers or other Persons pursuant to Contracts entered into in the ordinary course of business;

 

(iv) any
Contract that purports to limit in any material respect the right of Jantibody (or, at any time after the consummation of the Acquisition,
H-Cyte or any of its Subsidiaries) to (A) engage in any line of business, (B) compete with any Person or solicit any client or customer,
or (C) operate in any geographical location;

 

(v) any
Contract relating to the disposition or acquisition, directly or indirectly (by acquisition, sale of stock, sale of assets, or otherwise),
by Jantibody after the date of this Agreement of assets or capital stock or other equity interests of any Person, in each case with a
fair market value in excess of $75,000;

 

(vi) any
Contract that grants any right of first refusal, right of first offer, or similar right with respect to any material assets, rights,
or properties of Jantibody;

 

    	20

     

    

 

(vii) any
Contract that contains any provision that requires the purchase of all or a material portion of Jantibody’s requirements for a
given product or service from a given third party, which product or service is material to Jantibody, taken as a whole;

 

(viii) any
Contract that obligates Jantibody to conduct business on an exclusive or preferential basis or that contains a “most favored nation”
or similar covenant with any third party or upon consummation of the Acquisition will obligate H-Cyte to conduct business on an exclusive
or preferential basis or that contains a “most favored nation” or similar covenant with any third party;

 

(ix) any
partnership, joint venture, limited liability company agreement, or similar Contract relating to the formation, creation, operation,
management, or control of any material joint venture, partnership, or limited liability corporation;

 

(x) any
mortgages, indentures, guarantees, loans, or credit agreements, security agreements, or other Contracts, in each case relating to indebtedness
for borrowed money, whether as borrower or lender, in each case in excess of $75,000, other than accounts receivables and payables;

 

(xi) any
employee collective bargaining agreement or other Contract with any labor union;

 

(xii) any
Contract relating to Intellectual Property;

 

(xiii) any
other Contract under which Jantibody is obligated to make payment or incur costs in excess of $75,000 in any year and which is not otherwise
described in clauses (i)–(xii) above; or

 

(xiv) any
Contract which is not otherwise described in clauses (i)-(xiii) above that is material to Jantibody, taken as a whole.

 

(b) Schedule
of Material Contracts; Documents. Schedule 3.14(b) of the Jantibody Disclosure Letter sets forth a true and complete list as of the
date hereof of all Jantibody Material Contracts. Jantibody has made available to H-Cyte correct and complete copies of all Jantibody
Material Contracts, including any amendments thereto.

 

(c) No
Breach. (i) To Jantibody’s knowledge, all Jantibody Material Contracts are legal, valid, and binding on Jantibody, enforceable
against it in accordance with its terms, and is in full force and effect; (ii) neither Jantibody nor, to the knowledge of Jantibody,
any third party has violated any material provision of, or failed to perform any material obligation required under the provisions of,
any Jantibody Material Contract; and (iii) neither Jantibody nor, to the knowledge of Jantibody, any third party is in material breach,
or has received written notice of breach, of any Jantibody Material Contract.

 

    	21

     

    

 

Section
3.15 Insurance. Jantibody does not hold any insurance policies.

 

Section
3.16 Anti-Corruption Matters. Since December 31, 2020, no Jantibody director, officer or, to the knowledge of Jantibody, employee
or agent of Jantibody has: (i) used any funds for unlawful contributions, gifts, entertainment, or other unlawful payments relating to
an act by any Governmental Entity; (ii) made any unlawful payment to any foreign or domestic government official or employee or to any
foreign or domestic political party or campaign or violated any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended;
or (iii) made any other unlawful payment under any applicable Law relating to anti-corruption, bribery, or similar matters. Since January
1, 2019, Jantibody has not disclosed to any Governmental Entity that it violated or may have violated any Law relating to anti-corruption,
bribery, or similar matters. To the knowledge of Jantibody, no Governmental Entity is investigating, examining, or reviewing Jantibody’s
compliance with any applicable provisions of any Law relating to anti-corruption, bribery, or similar matters.

 

Section
3.17 Assets of AperiSys, Inc. Jantibody has good and marketable title to substantially all of the assets formerly owned by AperiSys,
as reflected in the books and records of AperiSys, free and clear of any Liens, other than Permitted Liens.

 

ARTICLE
IV 

REPRESENTATIONS
AND WARRANTIES OF H-CYTE

 

Except:
(a) as disclosed in the H-Cyte Public Documents at least (5) five business days prior to the date hereof and as identified in the particular
representation that is reasonably apparent on the face of such disclosure to be applicable to the representation and warranty set forth
herein (other than any disclosures contained or referenced therein under the captions “Risk Factors,” “Forward-Looking
Statements,” “Quantitative and Qualitative Disclosures About Market Risk,” and any other disclosures contained or referenced
therein of information, factors, or risks that are predictive, cautionary, or forward-looking in nature); or (b) as set forth in the
correspondingly numbered Section of the H-Cyte Disclosure Letter that relates to such Section or in another Section of the H-Cyte Disclosure
Letter to the extent that it is reasonably apparent on the face of such disclosure that such disclosure is applicable to such Section;
H-Cyte hereby represents and warrants to Jantibody and to the Jantibody Members as follows:

 

Section
4.01 Organization; Standing and Power; Charter Documents; Subsidiaries.

 

(a) Organization;
Standing and Power. Each of H-Cyte and its Subsidiaries is a corporation, limited liability company, or other legal entity duly organized,
validly existing, and in good standing (to the extent that the concept of “good standing” is applicable in the case of any
jurisdiction outside the United States) under the Laws of its jurisdiction of organization, and has the requisite corporate, limited
liability company, or other organizational, as applicable, power and authority to own, lease, and operate its assets and to carry on
its business as now conducted. Each of H-Cyte and its Subsidiaries is duly qualified or licensed to do business as a foreign corporation,
limited liability company, or other legal entity and is in good standing (to the extent that the concept of “good standing”
is applicable in the case of any jurisdiction outside the United States) in each jurisdiction where the character of the assets and properties
owned, leased, or operated by it or the nature of its business makes such qualification or license necessary, except where the failure
to be so qualified or licensed or to be in good standing, would not reasonably be expected to have, individually or in the aggregate,
a H-Cyte Material Adverse Effect.

 

    	22

     

    

 

(b) Charter
Documents. The copies of the Articles of Incorporation and Bylaws of H-Cyte as most recently filed with the appropriate authorities
(the “H-Cyte Charter Documents”) are true, correct, and complete copies of such documents as in effect as of the date
of this Agreement. H-Cyte is not in violation of any of the provisions of the H-Cyte Charter Documents.

 

(c) Subsidiaries.
All of the outstanding shares of capital stock of, or other equity or voting interests in, each Subsidiary of H-Cyte has been validly
issued and are owned by H-Cyte, directly or indirectly, free of pre-emptive rights, are fully paid and nonassessable, and are free and
clear of all Liens, including any restriction on the right to vote, sell, or otherwise dispose of such capital stock or other equity
or voting interests, except for any Liens: (i) imposed by applicable securities Laws; or (ii) arising pursuant to the charter documents
of any non-wholly-owned Subsidiary of H-Cyte . Except for the capital stock of, or other equity or voting interests in, its Subsidiaries,
H-Cyte does not own, directly or indirectly, any capital stock of, or other equity or voting interests in, any Person.

 

(d) Valid
Issuance of Acquisition Consideration and Contingent Shares. The shares of H-Cyte Common Stock comprising the Acquisition Consideration
and the Contingent Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement,
will be validly issued, fully paid and nonassessable, and such shares will be issued in compliance with all applicable federal and state
securities laws.

 

Section
4.02 Capital Structure.

 

(a) Capital
Stock. The authorized capital stock of H-Cyte consists of: (i) 500,000,000 shares of H-Cyte Common Stock and 50,000,000 shares of
Preferred Stock. As of the date of this Agreement: 258,219 shares of H-Cyte Common Stock and • 493,642,117 shares of Series A
Preferred Stock were issued and outstanding. All of the outstanding shares of capital stock of H-Cyte are, and all shares of capital
stock of H-Cyte which may be issued as contemplated or permitted by this Agreement, including the shares of H-Cyte Common Stock constituting
part of the Acquisition Consideration, will be, when issued, duly authorized, validly issued, fully paid, and non-assessable, and not
subject to any pre-emptive rights. No Subsidiary of H-Cyte owns any shares of H-Cyte Common Stock. H-Cyte has provided the Jantibody
Members with a detailed capitalization of all securities convertible into H-Cyte Common Stock and its planned issuances.

 

(b) Stock
Awards. Except as disclosed in H-Cyte’s SEC filings, there are no options, warrants, conversion privileges or other rights,
agreements, arrangements or commitments (pre-emptive, contingent or otherwise) of any kind that obligate H-Cyte to issue or sell any
shares of capital stock or other securities of H-Cyte or any of its Subsidiaries or any securities or obligations convertible or exchangeable
into or exercisable for, or giving any Person a right to subscribe for or acquire, any securities of H-Cyte or any of its Subsidiaries.
The description of the H-Cyte’s capitalization on a fully diluted basis is as set forth in Schedule 4.02 of the H-Cyte Disclosure
Letter.

 

    	23

     

    

 

(c) Voting
Debt. No bonds, debentures, notes, or other indebtedness issued by H-Cyte or any of its Subsidiaries: (i) having the right to vote
on any matters on which stockholders or equity holders of H-Cyte or any of its Subsidiaries may vote (or which is convertible into, or
exchangeable for, securities having such right); or (ii) the value of which is directly based upon or derived from the capital stock,
voting securities, or other ownership interests of H-Cyte or any of its Subsidiaries, are issued or outstanding (collectively, “H-Cyte
Voting Debt”).

 

(d) H-Cyte
Subsidiary Securities. As of the date hereof, except as set forth in the H-Cyte Disclosure Letter, there are no outstanding: (i)
securities of H-Cyte or any of its Subsidiaries convertible into or exchangeable for H-Cyte Voting Debt, capital stock, voting securities,
or other ownership interests in any Subsidiary of H-Cyte ; (ii) options, warrants, or other agreements or commitments to acquire from
H-Cyte or any of its Subsidiaries, or obligations of H-Cyte or any of its Subsidiaries to issue, any H-Cyte Voting Debt, capital stock,
voting securities, or other ownership interests in (or securities convertible into or exchangeable for capital stock, voting securities,
or other ownership interests in) any Subsidiary of H-Cyte; or (iii) restricted shares, restricted stock units, stock appreciation rights,
performance shares, profit participation rights, contingent value rights, “phantom” stock, or similar securities or rights
that are derivative of, or provide economic benefits based, directly or indirectly, on the value or price of, any capital stock or voting
securities of, or other ownership interests in, any Subsidiary of H-Cyte, in each case that have been issued by a Subsidiary of H-Cyte.

 

Section
4.03 Authority; Non-Contravention; Governmental Consents; Board Approval.

 

(a) Authority.
H-Cyte has all requisite corporate power, and authority to enter into and to perform its obligations under this Agreement and, subject
to, in the case of the consummation of the Acquisition (“Requisite H-Cyte Approval”), to consummate the transactions
contemplated by this Agreement. The execution and delivery of this Agreement by H-Cyte and the consummation by H-Cyte of the transactions
contemplated by this Agreement have been duly authorized by all necessary corporate action, as applicable, on the part of H-Cyte and
no other corporate proceedings on the part of H-Cyte are necessary to authorize the execution and delivery of this Agreement by H-Cyte
or to consummate the Acquisition and the other transactions contemplated by this Agreement, subject only, in the case of the consummation
of the Acquisition, to obtain the Requisite H-Cyte Approval. This Agreement has been duly executed and delivered by H-Cyte and assuming
due execution and delivery by Jantibody and the Jantibody Members, constitutes the legal, valid, and binding obligation of H-Cyte and
enforceable against H-Cyte in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium,
and other similar Laws affecting creditors’ rights generally and by general principles of equity.

 

    	24

     

    

 

(b) Non-Contravention.
The execution, delivery, and performance of this Agreement by H-Cyte and the consummation by H-Cyte of the transactions contemplated
by this Agreement, do not and will not: (i) contravene or conflict with, or result in any violation or breach of, the H-Cyte Charter
Documents; (ii) assuming that all of the Consents contemplated by Section 4.03(c) have been obtained or made, and in the case of the
consummation of the Acquisition, conflict with or violate any Law applicable to H-Cyte or any of its properties or assets; (iii) result
in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in H-Cyte’s or any of its Subsidiaries’ loss of any benefit or the imposition of any additional payment or other Liability
under, or alter the rights or obligations of any third party under, or give to any third party any rights of termination, amendment,
acceleration, or cancellation, or require any Consent under, any Contract to which H-Cyte or any of its Subsidiaries is a party or otherwise
bound as of the date hereof; or (iv) result in the creation of a Lien (other than Permitted Liens) on any of the properties or assets
of H-Cyte or any of its Subsidiaries, except, in the case of each of clauses (ii), (iii), and (iv), for any conflicts, violations, breaches,
defaults, loss of benefits, additional payments or other liabilities, alterations, terminations, amendments, accelerations, cancellations,
or Liens that, or where the failure to obtain any Consents, in each case, would not reasonably be expected to have, individually or in
the aggregate, a H-Cyte Material Adverse Effect.

 

(c) Governmental
Consents. No Consent of any Governmental Entity is required to be obtained or made by H-Cyte in connection with the execution, delivery,
and performance by H-Cyte of this Agreement or the consummation by H-Cyte of the Acquisition and the other transactions contemplated
hereby, except for: (i) such Consents as may be required under applicable state securities or “blue sky” Laws and the securities
Laws of any foreign country or the rules and regulations of the OTC Markets; and (iii) such other Consents which if not obtained or made
would not reasonably be expected to have, individually or in the aggregate, an H-Cyte Material Adverse Effect.

 

(d) Board
Approval. The H-Cyte Board by resolutions duly adopted by a unanimous vote at a meeting of all directors of H-Cyte duly called and
held and, not subsequently rescinded or modified in any way, has (A) determined that this Agreement and the transactions contemplated
hereby, including the Acquisition, and the payment of the Acquisition Consideration, upon the terms and subject to the conditions set
forth herein, are fair to, and in the best interests of, H-Cyte and its stockholders, and (B) approved and declared advisable this Agreement,
including the execution, delivery, and performance thereof, and the consummation of the transactions contemplated by this Agreement,
including the Acquisition, upon the terms and subject to the conditions set forth herein.

 

    	25

     

    

 

Section
4.04 Public Filings; Financial Statements; Undisclosed Liabilities.

 

(a)
Public Filings. H-Cyte has timely filed with or furnished to, as applicable, the Securities Exchange Commission (the “SEC”),
all material registration statements, prospectuses, reports, schedules, forms, statements, and other documents (including exhibits and
all other information incorporated by reference) required to be filed or furnished by it with the SEC since January 1, 2020 (the “H-Cyte
Public Documents”). H-Cyte is a reporting issuer, or the equivalent thereof, in Nevada (the “Reporting Jurisdiction”),
and is not currently in default of any requirement of the applicable Laws of the Reporting Jurisdiction and other regulatory instruments
of the securities authorities in the Reporting Jurisdiction, and no order ceasing, halting or suspending trading in securities of H-Cyte
or prohibiting the distribution of such securities has been issued to and is outstanding against H-Cyte and no investigations or proceedings
for such purposes are, to the knowledge of H-Cyte, pending or threatened. H-Cyte is in compliance in all material respects with all its
disclosure obligations under applicable Laws and all documents filed by H-Cyte pursuant to such obligations are in compliance in all
material respects with applicable Laws and, other than in respect of documents that have been amended or refiled, did not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.

 

(b) Financial
Statements. Each of the consolidated financial statements (including, in each case, any notes and schedules thereto) contained in
or incorporated by reference into the H-Cyte Public Documents: (i) complied as to form in all material respects with GAAP with respect
thereto as of their respective dates; (ii) was prepared in accordance with GAAP applied on a consistent basis throughout the periods
involved (except as may be indicated in the notes thereto and, in the case of unaudited interim financial statements, as may be permitted
by the GAAP for Quarterly Reports on Form 10-Q); and (iii) fairly presented in all material respects the consolidated financial position
and the results of operations, changes in stockholders’ equity, and cash flows of H-Cyte and its consolidated Subsidiaries as of
the respective dates of and for the periods referred to in such financial statements, subject, in the case of unaudited interim financial
statements, to normal and year-end audit adjustments as permitted by GAAP and the applicable rules and regulations of the SEC (but only
if the effect of such adjustments would not, individually or in the aggregate, be material).

 

(c) Undisclosed
Liabilities. The audited balance sheet of H-Cyte dated as of December 31, 2021 contained in the H-Cyte Public Documents filed prior
to the date hereof is hereinafter referred to as the “H-Cyte Balance Sheet.” Neither H-Cyte nor any of its Subsidiaries
has any Liabilities other than Liabilities that: (i) are reflected or reserved against in the H-Cyte Balance Sheet (including in the
notes thereto); (ii) were incurred since the date of the H-Cyte Balance Sheet in the ordinary course of business consistent with past
practice; (iii) are incurred in connection with the transactions contemplated by this Agreement; or (iv) would not reasonably be expected
to have, individually or in the aggregate, a H-Cyte Material Adverse Effect.

 

(d) OTC
Compliance. H-Cyte is in compliance with all of the applicable listing and corporate governance rules of the OTC except for any non-compliance
that would not reasonably be expected to have, individually or in the aggregate, an H-Cyte Material Adverse Effect.

 

    	26

     

    

 

Section
4.05 Absence of Certain Changes or Events. Since the date of the H-Cyte Balance Sheet, except in connection with the execution
and delivery of this Agreement and the consummation of the transactions contemplated hereby, the business of H-Cyte and each of its Subsidiaries
has been conducted in the ordinary course of business consistent with past practice and there has not been or occurred any H-Cyte Material
Adverse Effect or any event, condition, change, or effect that could reasonably be expected to have, individually or in the aggregate,
a H-Cyte Material Adverse Effect.

 

Section
4.06 Taxes.

 

(a) Except
as disclosed in Schedule 4.06 of the H-Cyte Disclosure Letter, all Tax Returns required by applicable Laws to be filed with any Governmental
Entity by, or on behalf of, H-Cyte or any of its Subsidiaries have been filed when due in accordance with applicable Laws (taking into
account any applicable extensions), and all such material Tax Returns are complete and correct in all material respects.

 

(b) H-Cyte
and each of its Subsidiaries has paid, or has had paid on its behalf, or has collected, withheld and remitted to the appropriate Governmental
Entity all Taxes due and payable by them on a timely basis, other than those Taxes being contested in good faith and in respect of which
reserves have been provided in the most recently published consolidated financial statements of H-Cyte. H-Cyte and its Subsidiaries have
provided adequate accruals in accordance with GAAP in the most recently published consolidated financial statements of H-Cyte for any
Taxes of H-Cyte and each of its Subsidiaries for the period covered by such financial statements that have not been paid whether or not
shown as being due in any Tax Returns. Since the date of publication of the most recent consolidated financial statements of H-Cyte,
no material Liability in respect of Taxes not reflected in such financial statements or otherwise provided for has been assessed, proposed
to be assessed, incurred or accrued, other than in the ordinary course of business.

 

(c) No
material deficiencies, litigation, proposed adjustments or other matters in controversy exist or have been asserted with respect to Taxes
of H-Cyte or any of its Subsidiaries and neither H-Cyte nor any of its Subsidiaries is a party to any action or proceeding for assessment
or collection of Taxes and no such event has been asserted or, to the knowledge of H-Cyte, threatened against H-Cyte or any of its Subsidiaries
or any of their respective assets.

 

(d) There
are no currently effective material elections, agreements or waivers extending the statutory period or providing for any extension of
time with respect to the assessment or reassessment of any material Taxes, or of the filing of any material Tax Return or any payment
of material Taxes, by H-Cyte or any of its Subsidiaries.

 

    	27

     

    

 

Section
4.07 Compliance; Permits.

 

(a) H-Cyte
and each of its Subsidiaries are and, since January 1, 2019, to H-Cyte’s knowledge have been in compliance with, all Laws or Orders
applicable to H-Cyte or any of its Subsidiaries or by which H-Cyte or any of its Subsidiaries or any of their respective businesses or
properties is bound, except for such non-compliance that would not reasonably be expected to have, individually or in the aggregate,
a H-Cyte Material Adverse Effect. Since January 1, 2019, no Governmental Entity has issued any notice or notification stating that H-Cyte
or any of its Subsidiaries is not in compliance with any Law, except where such non-compliance would not reasonably be expected to have,
individually or in the aggregate, an H-Cyte Material Adverse Effect.

 

(b) Permits.
H-Cyte and its Subsidiaries hold, to the extent necessary to operate their respective businesses as such businesses are being operated
as of the date hereof, all Permits except for any Permits for which the failure to obtain or hold would not reasonably be expected to
have, individually or in the aggregate, a H-Cyte Material Adverse Effect. No suspension, cancellation, non-renewal, or adverse modifications
of any Permits of H-Cyte or any of its Subsidiaries is pending or, to the knowledge of H-Cyte, threatened, except for any such suspension
or cancellation which would not reasonably be expected to have, individually or in the aggregate, an H-Cyte Material Adverse Effect.
H-Cyte and each of its Subsidiaries is and, since January 1, 2019, has been in compliance with the terms of all Permits, except where
the failure to be in such compliance would not reasonably be expected to have, individually or in the aggregate, a H-Cyte Material Adverse
Effect.

 

Section
4.08 Litigation. Except as disclosed in Schedule 4.08 of the H-Cyte Disclosure Letter, there is no Legal Action pending, or to
the knowledge of H-Cyte, threatened against H-Cyte or any of its Subsidiaries or any of their respective properties or assets or, to
the knowledge of H-Cyte, any officer or director of H-Cyte or any of its Subsidiaries in their capacities as such other than any such
Legal Action that: (a) does not involve an amount that would reasonably be expected to have, individually or in the aggregate, a H-Cyte
Material Adverse Effect; and (b) does not seek material injunctive or other material non-monetary relief. None of H-Cyte or any of its
Subsidiaries or any of their respective properties or assets is subject to any Order of a Governmental Entity or arbitrator, whether
temporary, preliminary, or permanent, which would reasonably be expected to have, individually or in the aggregate, a H-Cyte Material
Adverse Effect. To the knowledge of H-Cyte, there are no SEC inquiries or investigations, other governmental inquiries or investigations,
or internal investigations pending or, to the knowledge of H-Cyte, threatened, in each case regarding any accounting practices of H-Cyte
or any of its Subsidiaries or any malfeasance by any officer or director of H-Cyte.

 

Section
4.09 Brokers’ and Finders’ Fees. Neither H-Cyte nor any of its Affiliates has incurred, nor will it incur, directly
or indirectly, any Liability for investment banker, brokerage, or finders’ fees or agents’ commissions, or any similar charges
in connection with this Agreement or any transaction contemplated hereby for which Jantibody or any Jantibody Member would be liable
in connection with the Acquisition. For purposes of this Agreement, an “Affiliate” of any particular Person means
any other Person controlling, controlled by or under common control with such particular Person, where “control” means
the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership
of voting securities, contract, or otherwise.

 

    	28

     

    

 

Section
4.10 Material Contracts. For purposes of this Agreement, “H-Cyte Material Contract” shall mean any Contract
that is material to H-Cyte and its Subsidiaries, taken as a whole. All H-Cyte Material Contracts are legal, valid, and binding on H-Cyte
or its applicable Subsidiary, enforceable against it in accordance with its terms, and is in full force and effect; (ii) neither H-Cyte
nor any of its Subsidiaries nor, to the knowledge of H-Cyte, any third party has violated any material provision of, or failed to perform
any material obligation required under the provisions of, any H-Cyte Material Contract; and (iii) neither H-Cyte nor any of its Subsidiaries
nor, to the knowledge of H-Cyte, any third party is in material breach, or has received written notice of breach, of any H-Cyte Material
Contract.

 

Section
4.11 Ownership of H-Cyte Common Stock. Neither H-Cyte nor any of its Affiliates or associates is the “beneficial owner”
(as defined in Regulation D promulgated under the Securities Act of 1933, as amended) of any shares of H-Cyte Common Stock.

 

Section
4.12 Intended Tax Treatment. Neither H-Cyte nor any of its Subsidiaries has taken or agreed to take any action, and to the knowledge
of H-Cyte there exists no fact or circumstance that is reasonably likely, to prevent or impede the Acquisition from qualifying as a “reorganization”
within the meaning of Section 368(a) of the Code. This Section shall in no way serve as a representation of H-Cyte that the transaction
is tax free to the Jantibody Members.

 

ARTICLE
V 

REPRESENTATIONS
AND WARRANTIES OF THE JANTIBODY MEMBERS

 

Each
Jantibody Member, severally but not jointly with any other Jantibody Member, represents and warrants to H-Cyte that (i) such Jantibody
Member is the true and lawful owner, of record and beneficially, of the Purchased Interest owned by such Jantibody Member, free and clear
of any Liens, (ii) no understanding, agreement (either express or implied), or reasonable expectancy of agreement with respect to the
sale or transfer of the Purchased Interest owned by such Jantibody Member exists between such Jantibody Member and any third party (other
than H-Cyte), and (iii) there are no (A) outstanding or authorized options, warrants, or convertible securities of any kind to acquire
from such Jantibody Member any equity or debt securities of Jantibody or securities convertible into or exchangeable for equity or debt
securities of Jantibody; or (B) other rights, agreements, arrangements or commitments of any character relating to the Purchased Interest
owned by such Jantibody Member that would be binding on H-Cyte as the successor owner thereof or would encumber such Purchased Interest.

 

ARTICLE
VI 

COVENANTS

 

Section
6.01 Notices of Certain Events; Stockholder Litigation; No Effect on Disclosure Letters.

 

(a) Notices
of Certain Events. Jantibody shall notify H-Cyte, and H-Cyte shall notify Jantibody, promptly of: (i) any notice or other communication
from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this
Agreement; and (ii) any notice or other communication from any Governmental Entity in connection with the transactions contemplated by
this Agreement.

 

    	29

     

    

 

(b) No
Effect on Disclosure Letters. In no event shall: (i) the delivery of any notice by a party pursuant to this Section 6.01 limit or
otherwise affect the respective rights, obligations, representations, warranties, covenants, or agreements of the parties or the conditions
to the obligations of the parties under this Agreement; (ii) disclosure by Jantibody be deemed to amend or supplement the Jantibody Disclosure
Letter or constitute an exception to Jantibody’s representations or warranties; or (iii) disclosure by H-Cyte be deemed to amend
or supplement the H-Cyte Disclosure Letter or constitute an exception to H-Cyte’s representations or warranties.

 

Section
6.02 Public Announcements. The initial press release with respect to this Agreement and the transactions contemplated hereby shall
be a release mutually agreed to by Jantibody and H-Cyte. Thereafter, each of Jantibody, H-Cyte and each Jantibody Member agrees that
no public release or announcement concerning the transactions contemplated hereby shall be issued by any party without the prior written
consent of Jantibody and H-Cyte (which consent shall not be unreasonably withheld, conditioned, or delayed), except as may be required
by applicable Law or the rules or regulations of any applicable securities exchange or other Governmental Entity to which the relevant
party is subject or submits, in which case the party required to make the release or announcement shall use its reasonable best efforts
to allow the other party reasonable time to comment on such release or announcement in advance of such issuance.

 

Section
6.03 Anti-Takeover Statutes. If any “control share acquisition,” “fair price,” “moratorium,”
or other anti-takeover Law becomes or is deemed to be applicable to the transaction contemplated by this Agreement, then each of Jantibody
and the Jantibody Board on the one hand, and H-Cyte and the H-Cyte Board on the other hand, shall grant such approvals and take such
actions as are necessary so that the transactions contemplated hereby may be consummated as promptly as practicable on the terms contemplated
hereby and otherwise act to render such anti-takeover Law inapplicable to the foregoing.

 

Section
6.04 Stock Exchange Matters. H-Cyte shall use its best efforts to cause the shares of H-Cyte Common Stock to be issued in connection
with the Acquisition to be listed on the OTC (or such other stock exchange as may be mutually agreed upon by Jantibody and H-Cyte), subject
to official notice of issuance, prior to the Closing Date.

 

Section
6.05 Cooperation. The parties agree to cooperate with each other and use reasonable best efforts to promptly prepare and file
all necessary documentation, to effect all applications, notices, petitions and filings, and to obtain as promptly as practicable any
consents, approvals and authorizations of all third parties and governmental bodies which are necessary or advisable to consummate this
Agreement and to comply with the terms and conditions of all such consents, approvals and authorizations of all such third parties and
governmental bodies.

 

    	30

     

    

 

ARTICLE
VII 

MISCELLANEOUS

 

Section
7.01  Interpretation; Construction.

 

(a) The
headings herein are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise
affect any of the provisions hereof. Where a reference in this Agreement is made to a Section, Exhibit, Article, or Schedule, such reference
shall be to a Section of, Exhibit to, Article of, or Schedule of this Agreement unless otherwise indicated. Unless the context otherwise
requires, references herein: (i) to an agreement, instrument, or other document means such agreement, instrument, or other document as
amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof; and (ii) to a statute means
such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder.
Whenever the words “include,” “includes,” or “including” are used in this Agreement, they shall be
deemed to be followed by the words “without limitation,” and the word “or” is not exclusive. The word “extent”
in the phrase “to the extent” means the degree to which a subject or other thing extends, and does not simply mean “if.”
A reference in this Agreement to $ or dollars is to U.S. dollars. The definitions of terms herein shall apply equally to the singular
and plural forms of the terms defined. The words “hereof,” “herein,” “hereby,” “hereto,”
and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not
to any particular provision of this Agreement. References to “this Agreement” shall include the Jantibody Disclosure Letter
and the H-Cyte Disclosure Letter.

 

(b) The
parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent
or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

Section
7.02  Survival. No representation, warranty, covenant or agreement of the parties contained in this Agreement contained in this
Agreement or in any instrument delivered under this Agreement will survive the Closing Date, except (i) any representation, warranty,
covenant or agreement of the parties contained in this Agreement which, by its terms, contemplates performance after the Closing Date,
and (ii) as follows:

 

(i) the
representations and warranties set out in ARTICLE III (Representations and Warranties Relating to Jantibody) shall continue in full force
and effect for a period of one (1) year after the Closing Date;

 

(ii) the
representations and warranties set out in ARTICLE IV (Representations and Warranties Relating to H-Cyte) shall continue in full force
and effect for a period of one (1) year after the Closing Date; and

 

    	31

     

    

 

(iii) any
claim for any breach of any of the representations and warranties contained in this Agreement or in any agreement, instrument, certificate
or other document executed or delivered pursuant hereto involving fraud or fraudulent misrepresentation may be made at any time following
the Closing Date, subject only to applicable limitation periods imposed by Law.

 

Section
7.03 Governing Law. This Agreement and all Legal Actions (whether based on contract, tort, or statute) arising out of, relating
to, or in connection with this Agreement or the actions of any of the parties hereto in the negotiation, administration, performance,
or enforcement hereof, shall be governed by and construed in accordance with the internal Laws of the State of Nevada without giving
effect to any choice or conflict of Law provision or rule (whether of the State of Nevada or any other jurisdiction) that would cause
the application of Laws of any jurisdiction other than those of the State of Nevada.

 

Section
7.04  Submission to Jurisdiction. Each of the parties hereto irrevocably agrees that any Legal Action with respect to this Agreement
and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and
the rights and obligations arising hereunder brought by any other party hereto or its successors or assigns shall be brought and determined
exclusively in the state and federal courts sitting in the State of New York, or in the event (but only in the event) that such courts
do not have subject matter jurisdiction over such Legal Action, then in the state and federal courts sitting in the State of Nevada.
Each of the parties hereto agrees that mailing of process or other papers in connection with any such Legal Action in the manner provided
in Section 7.06 or in such other manner as may be permitted by applicable Law, will be valid and sufficient service thereof. Each of
the parties hereto hereby irrevocably submits with regard to any such Legal Action for itself and in respect of its property, generally
and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it will not bring any Legal Action relating
to this Agreement or any of the transactions contemplated by this Agreement in any court or tribunal other than the aforesaid courts.
Each of the parties hereto hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim, or otherwise,
in any Legal Action with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement
of any judgment in respect of this Agreement and the rights and obligations arising hereunder: (a) any claim that it is not personally
subject to the jurisdiction of the above named courts for any reason other than the failure to serve process in accordance with this
Section 7.04; (b) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process
commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment,
execution of judgment or otherwise); and (c) to the fullest extent permitted by the applicable Law, any claim that (i) the suit, action,
or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action, or proceeding is improper, or (iii)
this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

 

Section
7.05  Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY
TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE
TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT: (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION; (B) SUCH PARTY HAS
CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY; AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER
INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.05.

 

    	32

     

    

 

Section
7.06  Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder shall be in writing
and shall be deemed to have been given upon the earlier of actual receipt or (a) when delivered by hand providing proof of delivery;
(b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); or (c) on the date sent
by email if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the
recipient. Such communications must be sent to the respective parties at the following addresses (or to such other Persons or at such
other address for a party as shall be specified in a written notice given in accordance with this Section 7.06):

 

	If
    to H-Cyte, to:	H-CYTE
INC.

    2202
N. West Shore Blvd, Suite 200

    Tampa,
FL

    Attention:
Jeremy Daniel, CFO

    Email:
    jdaniel@hcyte.com

	 	 
	with
    a copy (which will not constitute notice to H-Cyte) to:	Sichenzia
Ross Ference LLP

    1185
Avenue of the Americas

    New
York, NY 10036

    Attention:
Arthur Marcus

    Email:
    amarcus@srf.law

	 	 
	If
    to Jantibody, to:	Jantibody,
LLC

    335
Sophia Terrace

    St.
Augustine, Florida 32095

    Attention:
Michael W. Yurkowsky

    Email:
    michael@yp-group.com

	 	 
	with
    a copy (which will not  constitute notice to Jantibody) to:	The
Garden Law Group

    2911
Turtle Creek Boulevard, Suite 400

    Dallas,
Texas 75219

    Attention:
Warren W. Garden, Esq.

    Email:
warren@gardenlawgroup.com

	 	 
	If
    to any Jantibody Member, to:	The
address for such Jantibody Member

    set
    forth on Schedule A

 

    	33

     

    

 

Section
7.07 Entire Agreement. This Agreement (including the Schedule to this Agreement), the Jantibody Disclosure Letter and the H-Cyte
Disclosure Letter constitute the entire agreement among the parties with respect to the subject matter of this Agreement and supersede
all other prior agreements and understandings, both written and oral, among the parties to this Agreement with respect to the subject
matter of this Agreement. In the event of any inconsistency between the statements in the body of this Agreement, the H-Cyte Disclosure
Letter, and the Jantibody Disclosure Letter (other than an exception expressly set forth as such in the H-Cyte Disclosure Letter or Jantibody
Disclosure Letter), the statements in the body of this Agreement will control.

 

Section
7.08  No Third-Party Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their permitted assigns and
respective successors and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal
or equitable right, benefit, or remedy of any nature whatsoever under or by reason of this Agreement.

 

Section
7.09  Severability. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such
invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable
such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal, or unenforceable,
the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the greatest extent possible.

 

Section
7.10  Assignment. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Neither H-Cyte nor Jantibody on the other hand, may assign its rights or obligations hereunder without
the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned, or delayed. No Jantibody
Member may assign his or its rights or obligations hereunder without the prior written consent of H-Cyte and Jantibody, which consent
shall not be unreasonably withheld, conditioned, or delayed. No assignment shall relieve the assigning party of any of its obligations
hereunder.

 

Section
7.11  Remedies. Except as otherwise provided in this Agreement, any and all remedies expressly conferred upon a party to this
Agreement will be cumulative with, and not exclusive of, any other remedy contained in this Agreement, at Law, or in equity. The exercise
by a party to this Agreement of any one remedy will not preclude the exercise by it of any other remedy.

 

    	34

     

    

 

Section
7.12  Specific Performance.

 

(a) The
parties hereto agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the
terms hereof and that the parties shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches of this
Agreement or to enforce specifically the performance of the terms and provisions hereof in any court described in Section 7.04.

 

(b) Each
party further agrees that: (i) no such party will oppose the granting of an injunction or specific performance as provided herein on
the basis that the other party has an adequate remedy at Law or that an award of specific performance is not an appropriate remedy for
any reason at Law or equity; (ii) no such party will oppose the specific performance of the terms and provisions of this Agreement; and
(iii) no other party or any other Person shall be required to obtain, furnish, or post any bond or similar instrument in connection with
or as a condition to obtaining any remedy referred to in this Section 7.12, and each party irrevocably waives any right it may have to
require the obtaining, furnishing, or posting of any such bond or similar instrument.

 

Section
7.13  Counterparts; Effectiveness. This Agreement may be executed in any number of counterparts, all of which will be one and
the same agreement. This Agreement will become effective when each party to this Agreement will have received counterparts signed by
all of the other parties.

 

[SIGNATURE
PAGES FOLLOW]

 

    	35

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above individually or by their
respective officers thereunto duly authorized, as applicable.

 

	 	JANTIBODY:
	 	 
	 	JANTIBODY,
    LLC
	 	 
	 	By: 	 
	 	Name: 	Michael W. Yurkowsky
	 	Title:	 President
	 	 
	 	H-CYTE:
	 	 
	 	H-CYTE,
    INC.
	 	 
	 	By:	 
	 	Name:	 Jeremy D. Daniel
	 	Title:	 Chief Financial Officer
	 	 
	 	JANTIBODY
    MEMBERS:
	 	 
	 	APERISYS,
    INC.
	 	 
	 	By:	 
	 	Name: 	Michael W. Yurkowsky
	 	Title: 	President
	 	 
	 	YPH,
    LLC
	 	 
	 	By:	 
	 	Name: 	Michael W. Yurkowsky
	 	Title: 	Manager

 

Signature
Page to Acquisition Agreement

 

    	 

     

    

 

	 	YPSILON
    BIOTECH, LLC
	 	 
	 	By:	 
	 	Name: 	Michael W. Yurkowsky
	 	Title: 	President
	 	 
	 	BRIAN
    E. JONES & pEGGY A. JONES JTWROS
	 	 
	 	By:	 
	 	 	Brian E. Jones
	 	 
	 	By:	 
	 	 	Peggy A. Jones
	 	 
	 	DONALD
    E. gARLIKOV
	 	 
	 	By:	 
	 	 	Donald E. Garlikov
	 	 
	 	PHILLIP
    TODD HERNDON
	 	 
	 	By:	 
	 	 	Phillip Todd Herndon
	 	 
	 	REX
    A. JONES
	 	 
	 	By:	 
	 	 	Rex A. Jones
	 	 
	 	NADG
    (APERISYS) INVESTMENTS LLLP
	 	 
	 	By:	 
	 	Name:	 Robert S. Green
	 	Title: 	Authorized Signatory
	 	 
	 	LUCIUS
    PARTNERS, LLC
	 	 
	 	By:	 
	 	Name: 	James Ahern
	 	Title: 	Managing Partner
	 	 
	 	JEFFREY
    GELFAND
	 	 
	 	By:	 
	 	 	Jeffrey Gelfand

 

Signature
Page to Acquisition Agreement

 

    	 

     

    

 

Schedule
A

 

	Name and
    address of Jantibody Member	 	Sharing
    Ratio

 Owned	 	 	Shares
    of H-Cyte

    Common Stock to be

 Received	 
	 	 	 	 	 	 	 
	AperiSys,
    Inc. 

    335
    Sophia Terrace 

    St.
    Augustine, Florida 32095 

    Attention:
    Michael W. Yurkowsky 

    Email:
    michael@yp-group.com 
	 	 	51.00	%	 	 	26,532	 
	 	 	 	 	 	 	 	 	 
	YPH,
    LLC 

    335
    Sophia Terrace 

    St.
    Augustine, Florida 32095 

    Attention:
    Michael W. Yurkowsky 

    Email:
    michael@yp-group.com 
	 	 	25.00	%	 	 	13,006	 
	 	 	 	 	 	 	 	 	 
	Ypsilon
    Biotech, LLC 

    335
    Sophia Terrace 

    St.
    Augustine, Florida 32095 

    Attention:
    Michael W. Yurkowsky 

    Email:
    michael@yp-group.com 
	 	 	10.00	%	 	 	5,202	 
	 	 	 	 	 	 	 	 	 
	Donald
    Garlikov 

     

    Email:
deg@ergdeg.com 
	 	 	2.14	%	 	 	1,113	 
	 	 	 	 	 	 	 	 	 
	NADG
    (Aperisys) Investments LLLP 

    2851
    John Street, Suite One,  

    Markham,
    Ontario M5R 2E3  

    Attention:
    Maureen Sharp 

    Email:
    msharp@nadg.com 
	 	 	4.00	%	 	 	2,081	 
	 	 	 	 	 	 	 	 	 
	Lucius
    Partners, LLC 

     

    Email:
    jahern@laidlawltd.com
	 	 	3.00	%	 	 	1,561	 
	 	 	 	 	 	 	 	 	 
	Jeffrey
    Gelfand 

    Apt
    208, 130 Mount Auburn St 

    Cambridge,
    Ma. 02138 

    Attention:
    Dr. Jeffrey Gelfand 

    Email:
    JGELFAND@mgh.harvard.edu 
	 	 	2.00	%	 	 	1,040	 
	 	 	 	 	 	 	 	 	 
	Phillip
    Todd Herndon 

     

    Email:
    Herndon_todd@msn.com 
	 	 	0.715	%	 	 	372	 
	 	 	 	 	 	 	 	 	 
	Rex
    Jones

     

    Email:
    rexajones@comcast.net 
	 	 	0.715	%	 	 	372	 
	 	 	 	 	 	 	 	 	 
	Brian
    E. Jones & Peggy A. Jones JTWROS 

     

    Email:
    bjones8629@yahoo.com 
	 	 	1.43	%	 	 	744	 
	Totals	 	 	100.00	%	 	 	52,023	 

 

    	A-1

     

    

 

SCHEDULE
B

 

As of August 31, 2022

 

	 	 	Pre-Acquisition Shares by Type	 	 	Shares of H-CYTE Common Stock Issued to Jantibody	 	 	Post Acquistion Shares by Type	 
	Common Stock Outstanding	 	 	294,798	 	 	 	52,023	 	 	 	346,821	 
	 	 	 	 	 	 	 	 	 	 	 	-	 
	Series A Preferred Outstanding (post 1000/1 reverse split)	 	 	457,065	 	 	 	80,659	 	 	 	537,724	 
	Warrants Outstanding	 	 	386,890	 	 	 	68,275	 	 	 	455,165	 
	Options Outstanding	 	 	19,749	 	 	 	3,485	 	 	 	23,234	 
	HCYTE Convertible Note Conversion	 	 	1,834,776	 	 	 	323,784	 	 	 	2,158,560	 
	Sub-Total	 	 	2,698,480	 	 	 	476,203	 	 	 	3,174,683	 
	 	 	 	 	 	 	 	 	 	 	 	-	 
	Total	 	 	2,993,278	 	 	 	528,226	 	 	 	3,521,504	 

 

    	B-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]